ストックスクリーナーアプリを入手
14.95
2.75%
0.40
アフターアワーズ：
14.95
前日終値:
$14.55
開ける：
$14.57
24時間の取引高:
96,293
Relative Volume:
0.66
時価総額：
$198.92M
収益：
$116.26M
当期純損益:
$-11.08M
株価収益率:
-18.88
EPS:
-0.7917
ネットキャッシュフロー:
$1.04M
1週間 パフォーマンス:
-2.03%
1か月 パフォーマンス:
+1.01%
6か月 パフォーマンス:
+51.78%
1年 パフォーマンス:
+3.17%
1日の値動き範囲:
$14.57
$15.18
1週間の範囲:
$11.92
$15.69
52週間の値動き範囲:
$7.8701
$16.24
Anika Therapeutics Inc Stock (ANIK) Company Profile
名前
Anika Therapeutics Inc
セクター
電話
(781) 457-9000
住所
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, ZTS, TEVA, HLN, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
14.95 | 193.60M | 116.26M | -11.08M | 1.04M | -0.7917 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-17 | 開始されました | B. Riley Securities | Buy |
| 2024-11-01 | 繰り返されました | Barrington Research | Outperform |
| 2023-08-14 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 再開されました | Stephens | Equal-Weight |
| 2022-03-09 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 開始されました | Stephens | Overweight |
| 2021-07-16 | 開始されました | UBS | Neutral |
| 2020-12-16 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | アップグレード | Sidoti | Neutral → Buy |
| 2020-01-10 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 開始されました | BWS Financial | Sell |
| 2019-09-24 | 繰り返されました | Barrington Research | Outperform |
| 2019-09-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | アップグレード | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | ダウングレード | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | ダウングレード | Sidoti | Buy → Neutral |
| 2018-07-27 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | アップグレード | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 繰り返されました | Barrington Research | Outperform |
| 2016-05-09 | アップグレード | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 繰り返されました | Barrington Research | Outperform |
すべてを表示
Anika Therapeutics Inc (ANIK) 最新ニュース
Insider Buying: HENNEMAN JOHN B III Acquires 5,000 Shares of Ani - GuruFocus
Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work - MSN
Anika Therapeutics Q1 2026 earnings preview - MSN
Anika Therapeutics director John Henneman buys $73,319 in shares By Investing.com - Investing.com Canada
Anika Therapeutics director John Henneman buys $73,319 in shares - Investing.com
Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy - Stock Titan
President of Anika Therapeutics Picks Up 51% More Stock - Yahoo Finance
Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
ANIK | Anika Therapeutics Inc Insider Trading - Quiver Quantitative
Anika Therapeutics Projects $114 Million Revenue Growth for Fiscal 2026 - HarianBasis.co
Insider Buying: Stephen Griffin Acquires Shares of Anika Therape - GuruFocus
Anika Therapeutics (NASDAQ:ANIK) CEO Purchases $149,938.00 in Stock - MarketBeat
Anika Therapeutics Q1 2026 Financial Results: Revenue, Losses, and Key Financial Statements Overview - Minichart
Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock By Investing.com - Investing.com India
Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock - Investing.com
Insider Purchase: President and CEO of $ANIK Buys 12,200 Shares - Quiver Quantitative
Anika Therapeutics (ANIK) CEO buys 12,200 shares in open market - Stock Titan
Anika Therapeutics : 2026 Proxy Statement - marketscreener.com
Bullish On Anika Therapeutics’s Pullback As Integrity Scales (NASDAQ:ANIK) - Seeking Alpha
Rotator cuff procedure advances driven by biology, Anika Therapeutics claims - Traders Union
(ANIK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2026 Earnings Call Transcript - Insider Monkey
Revenue climbs 13% as Anika Therapeutics (NASDAQ: ANIK) boosts margins but stays in loss - Stock Titan
Anika Therapeutics Inc (ANIK) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments - GuruFocus
Anika Therapeutics (ANIK) Q4 Profit Challenges Ongoing Unprofitability Narrative Ahead Of Q1 Earnings - simplywall.st
Anika Therapeutics Signals Momentum Amid Regulatory Hurdles - TipRanks
Vanguard (ANIK) discloses 695,697 shares, a 5.19% stake (Schedule 13G) - Stock Titan
Anika Therapeutics (NASDAQ:ANIK) Releases Earnings Results, Misses Expectations By $0.17 EPS - MarketBeat
Anika Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Anika Therapeutics Posts Strong Q1 2026 Revenue Growth - TipRanks
Earnings Call Summary | Anika Therapeutics(ANIK.US) Q1 2026 Earnings Conference - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Anika (ANIK) Q1 2026 Earnings Transcript - AOL.com
Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
ANIK Reports Q1 Revenue Growth Driven by Strong Commercial Chann - GuruFocus
Anika Therapeutics Q1 Earnings Call Highlights - MarketBeat
Is Anika Therapeutics (ANIK) 30.3% Undervalued After Q1 2026 Ear - GuruFocus
Earnings call transcript: Anika Therapeutics Q1 2026 beats EPS forecast By Investing.com - Investing.com Australia
Earnings call transcript: Anika Therapeutics Q1 2026 beats EPS forecast - Investing.com
Anika Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ANIK) 2026-04-29 - Seeking Alpha
ANIKA THERAPEUTICS ($ANIK) Releases Q1 2026 Earnings - Quiver Quantitative
Anika Therapeutics board members William R. Jellison and Glenn R. Larsen resign ahead of 2026 annual meeting - TradingView
Double-digit Q1 growth at Anika (NASDAQ: ANIK) as margins rise - Stock Titan
Anika: Q1 Earnings Snapshot - 10TV
Anika Reports First Quarter 2026 Financial Results - The Manila Times
Anika Therapeutics, Inc. Maintains Earnings Guidance for Fiscal Year 2026 - marketscreener.com
Anika Therapeutics (NASDAQ: ANIK) details 2026 meeting, director votes and larger equity pools - Stock Titan
[ARS] Anika Therapeutics, Inc. SEC Filing - Stock Titan
Anika Therapeutics ends Shoulder360 weekend by inviting demo requests for Integrity product - Traders Union
Integrity Implant System introduced as Anika Therapeutics opens Shoulder360 conference - Traders Union
ANIK (Anika Therapeutics Inc.) swings to Q4 2025 profit against expected loss, shares edge higher.Earnings Quality - Xã Châu Thành
Anika Therapeutics Inc (ANIK) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):